A Cryptolepis Sanguinolenta-Based Preparation Reduced Hospital Stay and Mortality of Covid-19 Patients During the Pandemi

Bibliographic Data

ID20345864
AuthorsMohamed MUTOCHELUH (0000-0002-1396-5085, Kwame Nkrumah University of Science and Technology), Charles ANSAH (0000-0001-6044-6117, Kwame Nkrumah University of Science and Technology), Kwame Ohene Buabeng (0000-0001-7944-2255, University of Health and Allied Sciences), Sampson Twumasi-Ankrah (0000-0002-9183-1883, Kwame Nkrumah University of Science and Technology), Seth Agyei DOMFEH (0000-0002-1689-7663, Kwame Nkrumah University of Science and Technology), Michael Owusu (0000-0001-5066-150X, Kwame Nkrumah University of Science and Technology), Michae OWUSU-ANSAH, Michael Owusu-Ansah (0000-0003-3631-0564, Komfo Anokye Teaching Hospital), Lawrence Sheringha BORQUAYE, Lawrence Sheringham Borquaye (0000-0002-5037-0777, Kwame Nkrumah University of Science and Technology), Evans Adei (0000-0003-2544-8883, Kwame Nkrumah University of Science and Technology), Christiana DUAH (Kumasi Technical University), Daniel Boamah (0000-0002-7662-7833, University of Ghana), Mavis BOAKYE-YIADOM, Mavis Boakye‐Yiadom (0000-0002-0488-1672, University of Ghana), Kofi Bobi Barimah, Ellis Owusu-Dabo, Ellis Owusu‐Dabo (0000-0003-4232-4292, Kwame Nkrumah University of Science and Technology)
Year2025
Volume20
Issue1
Pages1-11
Publication date2025-09-29
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueAfrican Journal of Traditional Complementary and Alternative Medicines (JOURNAL)
Journal identifiersISSN: 0189-6016 • E-ISSN: 2505-0044
PublisherAfrican Traditional Herbal Medicine Supporters Initiative (ATHMSI) (PUBLISHER)
DOI10.21010/ajtcamv21i1.1
OpenAlexW4413846409
LanguageEN

Background:In 2020, the World Health Organization urged nations to take domestic steps to curb the spread and contain the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, also referred to as coronavirus disease 2019 (COVID-19). In the meantime, there was growing clinical evidence that reported favourable effects of using herbal medicine in managingCOVID-19. We, therefore, repurposed Nibima (a Cryptolepis sanguinolenta-based herbal preparation) as an adjunct to conventional therapy for COVID-19. This was premised on our previous in vitroinvestigations that showed that Nibima has both antiviral and anti-inflammatory activities. Materials and Methods:This trial (FDA/CT/11) was an open-label, randomised controlled phase II pilot study, which was conducted from March 2021 to October 2022 among hospitalised COVID-19 patients in the Ashanti Region of Ghana. Participants were either randomised to aqua(water)or Nibima,the investigational product as adjunct to COVID therapy. Results:Nibima was well tolerated by the study participants, and the patients who were administered that together with the standard COVID-19 therapy had rapid clinical recovery compared to those taking aqua and the standardorconventional COVID-19 therapy. The evidence obtained provides a strong basis for future studies with large numbers of hospitalised patients with COVID-19 and other viral respiratory infections. Article HistoryReceived: June 11th2024Revised Received: April 13th2025 Accepted:April 14th2025Published Online: Aug. 29th2025 2Conclusion: Though COVID-19 is no longer a pandemic, it is still a public health challenge. We recommend that Nibima be further investigated for its broad-spectrum antiviral and immunomodulatory activities against SARS-COV-2 and other viral infections in preparedness for the re-emergence of future pandemics

2019-20 coronavirus outbreak · Betacoronavirus · Biology · Intensive care medicine · MEDLINE · Outbreak · Pandemic · Medicine · Synthesis and bioactivity of alkaloids · Emergency Medicine · Internal Medicine · Virology

Tools

Open DOIOpen Access